Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
The AAPS Journal|November 8, 2008
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspectiveEmily O Dumas, Gary M PollackClinical Pharmacology in Drug Development|April 30, 2016
A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteersNathan S Teuscher, Richard J Kelley, Emily O Dumas, et al.Plos One|June 1, 2018
Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimensAparna Vasanthakumar, Justin W Davis, Manal Abunimeh, et al.Clinical Pharmacokinetics|February 20, 2016
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy VolunteersAkshanth R Polepally, Jennifer R King, Bifeng Ding, et al.Antimicrobial Agents and Chemotherapy|March 8, 2017
Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling TechniquesCharles S Venuto, Marianthi Markatou, Yvonne Woolwine-Cunningham, et al.The Lancet. Gastroenterology & Hepatology|April 19, 2017
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trialTania M Welzel, Tarik Asselah, Emily O Dumas, et al.The International Journal on Drug Policy|February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapyJason Grebely, Gregory J Dore, Negar N Alami, et al.The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.Pageof 2